FABP4 and obesity due to melanocortin 4 receptor deficiency: Interestingly, mice treated with BMS309403 exhibited reduced symptoms of diabetes, atherosclerosis and mammary tumor growth [16, 34], suggesting that targeting FABP4 with small-molecular inhibitors might represent a promising approach for treating obesity-associated diseases.